Replies to post #109338 on Biotech Values

[iwfal]

the docs were saying that patients are not that interested in using Provenge because if they are going to be on a drug they want to see their PSA counts go down and their tumors shrink.

I take this the same way I take the docs saying that they won't prescribe non-Warfarin because INR doesn't work. Yeah, it requires a mindset change. And that is a financial risk for Provenge - but not a valid scientific one:

a) There are plenty (a majority) of drugs without quick markers of efficacy.

b) Provenge does actually have a marker - just a different one based upon a test during manufacturing.

b) Over the next 10 years there is a good chance that markers will be found and become prevalent that will work off blood tests - e.g. CTC.